NEXT GENERATION
CELL THERAPIES

Exosomes-based therapies : cell-free, safer, scale-up compatible.

Evora Biosciences acquires exclusive worldwide rights for digestive fistula treatment from Erganeo

April 8th 2020

Primary target : digestive fistula healing

Digestive fistula can be life-impairing for patients, and are linked to a variety of conditions or surgical procedures.

For complex cases, currently available therapeutic options for patients and clinicians are unsatisfactory. This can dramatically impact patient’s quality of life.

Our candidate EVOGEX-001 is the result of our first-in-class expertise in copolymer gels and exosomes, with the aim to significantly improve patient outcomes.

Exosomes : the next step in regenerative cell therapy

Exosomes are small vesicles produced by cells, from which they carry some very interesting properties. Stem-cells derived exosomes, in particular, are able to virtually replicate the regenerative properties of their parent cells.

Compared to stem cells, exosomes-based treatments offer simpler and more cost-efficient logistics, and greater ease of use for clinicians.

For patients, research has shown that exosomes have a more advantageous risk profile compared to stem cells : no donor rejection, no proliferation or differentiation risks.

The exosomes used in our treatments are produced with high-yield and scale-up compatible technologies. Compared to current-generation cell therapies, this allows for a 10x increase in production throughput in 10x less time.